Scientists hunt for blood test to predict deadly clots in cancer patients

NCT ID NCT07119970

Summary

This study aims to find better ways to predict which patients with certain blood cancers are most likely to develop dangerous blood clots. Researchers will follow 300 patients for two years, testing their blood for specific markers. The goal is to see if these markers can help doctors decide the best preventive treatment to reduce clot risk.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHO-Hôpital Saint-Louis, Centre d'Investigations Cliniques

    NOT_YET_RECRUITING

    Paris, 75010, France

    Contact Email: •••••@•••••

  • APHP-Hôpital Bicêtre, Service Hématologie Clinique Ambulatoire

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, 94270, France

    Contact Email: •••••@•••••

  • APHP-Hôpital Mondor, Service Hématologie Clinique et Thérapie Cellulaire

    NOT_YET_RECRUITING

    Créteil, 94010, France

    Contact Email: •••••@•••••

  • CH de Libourne, Service Hématologie

    RECRUITING

    Libourne, 33505, France

    Contact Email: •••••@•••••

  • CH de Roubaix, Service Hématologie

    NOT_YET_RECRUITING

    Roubaix, 59100, France

    Contact Email: •••••@•••••

  • CH de la Côte Basque, Service Hématologie

    NOT_YET_RECRUITING

    Bayonne, 64100, France

    Contact Email: •••••@•••••

  • CH des Pays de Morlaix, Service Onco-Hématologie

    NOT_YET_RECRUITING

    Morlaix, 29672, France

    Contact Email: •••••@•••••

  • CHD de Vendée, Service Onco-hématologie

    NOT_YET_RECRUITING

    La Roche-sur-Yon, 85925, France

    Contact Email: •••••@•••••

  • CHU d'Angers, Service des maladies du Sang

    NOT_YET_RECRUITING

    Angers, 49933, France

    Contact Email: •••••@•••••

  • CHU de Bordeaux, Service Hématologie Biologique

    NOT_YET_RECRUITING

    Bordeaux, 33600, France

    Contact Email: •••••@•••••

  • CHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire

    NOT_YET_RECRUITING

    Bordeaux, 33600, France

    Contact Email: •••••@•••••

  • CHU de Brest, Service Hématologie et Hémostase Clinique

    NOT_YET_RECRUITING

    Brest, 29609, France

    Contact Email: •••••@•••••

  • CHU de Limoges, Service Hématologie Clinique et de Thérapie Cellulaire

    NOT_YET_RECRUITING

    Limoges, 87042, France

    Contact Email: •••••@•••••

  • CHU de Nantes, Service Hématologie Clinique

    NOT_YET_RECRUITING

    Nantes, 44093, France

    Contact Email: •••••@•••••

  • Hôpital Privé du Confluent, Service Hématologie

    NOT_YET_RECRUITING

    Nantes, 44202, France

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.